Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
193.17
-0.23 (-0.12%)
Streaming Delayed Price
Updated: 11:38 AM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
AbbVie (ABBV) Q2 2024 Earnings Call Transcript
July 25, 2024
ABBV earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
July 25, 2024
Wall Street strongly rebounded Thursday after Wednesday’s slump, driven by stronger-than-expected economic growth in the last quarter, countering concerns of a slowdown.
Via
Benzinga
Topics
Economy
Exposures
Economy
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q2 2024
July 25, 2024
ABBV stock results show that AbbVie beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Peeling Back The Layers: Exploring AbbVie Through Analyst Insights
July 19, 2024
Via
Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today
July 18, 2024
Via
Benzinga
AbbVie Unusual Options Activity
July 17, 2024
Via
Benzinga
AbbVie Stock News: Why ABBV Is the Top Trending Ticker Today
July 25, 2024
AbbVie stock is the top trending ticker on Yahoo Finance Thursday earnings news has ABBV investors pumped up this morning.
Via
InvestorPlace
AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs
July 25, 2024
AbbVie Inc. reported Q2 adjusted EPS of $2.65, beating the $2.57 consensus, with net revenues at $14.46 billion. Immunology sales rose to $6.97 billion, while Humira declined 29.8%. Oncology and...
Via
Benzinga
Topics
Earnings
Exposures
Financial
AbbVie Slides Despite Beating Second-Quarter Views, Raising Guidance
July 25, 2024
The company's biggest drug, Humira, is about to give way to Skyrizi when it comes to sales power.
Via
Investor's Business Daily
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
July 25, 2024
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
AbbVie Unusual Options Activity
July 11, 2024
Via
Benzinga
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
July 25, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Is AbbVie the Best Dividend Stock for You?
July 25, 2024
The drug company has a famously strong dividend record -- and that looks set to continue.
Via
The Motley Fool
7 Trustworthy Dividend Stocks to Steadily Build Your Portfolio
July 24, 2024
With political rumblings poised to make things exciting, investors may turn to the stability of trustworthy dividend stocks.
Via
InvestorPlace
Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House
July 25, 2024
Sentiment continues to be jittery, with the major index futures priming for a lower opening on Thursday as traders look ahead to the first read of second-quarter GDP data and more earnings. The tech...
Via
Benzinga
Topics
Government
Stocks
Exposures
Political
US Equities
AbbVie Earnings Preview: Will Humira's Expiry, New CEO Fuel A Bullish Surge?
July 24, 2024
AbbVie will report Q2 earnings on Thursday. Investors watch for Humira impact and signs of recovery under new CEO.
Via
Benzinga
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
July 22, 2024
The big pharma company's top drug is losing ground, but its dividend keeps rising.
Via
The Motley Fool
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
July 21, 2024
The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season.
Via
Benzinga
10 Best Dividend Growth Stocks to Buy and Hold Forever
July 21, 2024
Discover 10 dividend growth powerhouses that could turbocharge your portfolio's long-term performance.
Via
The Motley Fool
7 High-Yield Dividend Stocks to Help Pay Your Bills
July 17, 2024
It’s time to stop actively generating wealth and let your money work for you with high-yield dividend stocks to buy.
Via
InvestorPlace
3 Absurdly Cheap Stocks to Buy and Hold for Years
July 17, 2024
You can buy these solid stocks at some attractive discounts right now.
Via
The Motley Fool
7 High-Yield Dividend Stocks Beating Inflation
July 16, 2024
High-yield dividend stocks are one of the surest paths to beating inflation as the cost of everything remains high in mid-2024.
Via
InvestorPlace
Topics
Economy
Exposures
Interest Rates
3 Quantum AI Stocks That Could Redefine Computing
July 16, 2024
Three quantum AI stocks could shape the future of computing, which means current market prices are very cheap.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
7 Recession-Proof Stocks to Shield Your Portfolio in 2024
July 16, 2024
Recession-proof stocks gain momentum as concerns about AI bubble grow and other factors contribute to needing to safeguard portfolios.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
3 Spinoff Stocks You Should Buy Now: July 2024
July 15, 2024
Spinoff stocks often take time to gain their footing in the market giving investors an opportunity to get in early.
Via
InvestorPlace
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
July 15, 2024
These companies stand out for their pedigrees, robust financials, and future growth prospects.
Via
The Motley Fool
3 Dividend Growth Stocks to Buy and Hold
July 14, 2024
What's better than a dividend? A dividend that's growing.
Via
The Motley Fool
3 High-Yield Dividend Stocks That Still Look Like Bargains
July 14, 2024
The prices of these reliable dividend payers haven't kept pace with the frothy stock market.
Via
The Motley Fool
AbbVie Appeals To Supreme Court Over Attorney-Client Privilege In 'Long-Standing' AndroGel Case
July 12, 2024
AbbVie petitions the U.S. Supreme Court to protect its corporate records, arguing a lower court ruling threatens attorney-client privilege.
Via
Benzinga
Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
July 11, 2024
The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.